RxDoctor Payments Data

Kevin Lawrence, MD

Pulmonary Disease · Fishersville, VANPI 1063513489

Payments from drug & device makers

$2,478in general payments, 2019–2025

Across 67 payments — averaging $36.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Regeneron Healthcare Solutions, Inc.$374
  • GSK$317
  • Amgen$140
  • AstraZeneca$126
  • Abbott$23
  • plus $27 from 2 others

What the payments were for

  • Travel & lodging$1,38056%
  • Food & beverage$1,09944%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,478 in reported general payments places this provider in the 45th percentile of 317 pulmonary disease providers in Virginia.

See all pulmonary disease providers in Virginia

Medicare billing

Part B allowed, 2024
$136,245
Medicare patients
574
Services billed
1,442

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate41$542,447
Trelegy ElliptaFluticasone/Umeclidin/Vilanter572$474,118
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr189$103,767
Spiriva RespimatTiotropium Bromide55$32,203
Stiolto RespimatTiotropium Br/Olodaterol Hcl42$29,801
Breo ElliptaFluticasone/Vilanterol37$27,792
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$22,007
Combivent RespimatIpratropium/Albuterol Sulfate25$13,294
Albuterol Sulfate HfaAlbuterol Sulfate422$9,307
Incruse ElliptaUmeclidinium Bromide17$8,891
SymbicortBudesonide/Formoterol Fumarate29$7,385
EliquisApixaban11$6,431
DuleraMometasone/Formoterol16$5,881
Arnuity ElliptaFluticasone Furoate14$4,164
BreynaBudesonide/Formoterol Fumarate20$3,939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$317$618,732829 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$126$33,22873 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 317 pulmonary disease providers in Virginia.

Other pulmonary disease in Fishersville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →